Eosinophil maturation/survival (mitochondrial)

Class

Eosinophil-lowering agent

Eosinophils are white blood cells that participate in immune defense against parasites and in allergic inflammation. When present in excess, they infiltrate tissues and release toxic granule proteins, contributing to diseases such as eosinophilic asthma, chronic rhinosinusitis, eosinophilic esophagitis, and hypereosinophilic syndromes. Most eosinophil-lowering therapies act on the interleukin-5 (IL-5) signaling axis, which drives eosinophil production and survival in the bone marrow and blood. This mechanism instead targets eosinophil maturation and survival through a mitochondrial pathway intrinsic to the developing cell, independent of IL-5 receptor signaling. By engaging mitochondrial processes that govern whether an eosinophil precursor completes maturation or undergoes programmed cell death, this approach can reduce eosinophil numbers even when IL-5 signaling is intact or when IL-5-directed therapies are insufficient. Because the mechanism is intracellular and lineage-related rather than dependent on a single surface receptor, it offers a mechanistically distinct route to eosinophil depletion, potentially broadening options for patients whose eosinophilic disease is not adequately controlled by receptor-blocking or ligand-neutralizing biologics. This class of agent is typically administered orally, in contrast to the injectable biologics that dominate IL-5-pathway targeting.